Thank you.
I think my colleague Bonnie Brown has zeroed in on one of the problems for many of us. I am one of the members who hasn't been here on drug review or drug pricing. And not being that familiar with CDR, according to what I've heard today, I think there's no contest; you should make the recommendation and we should follow it.
We will be hearing from Health Canada. We will be hearing from CDR. I would like to get a commitment from each of you that when we have questions—I for one certainly will have questions—we can call upon you individually to answer some of these questions. As you know, you're amongst the first; there are going to be people coming after you, countering your arguments.
Dr. Billen, you're a scientist. You are so passionate about this, you very well may be the last one to talk to all of us.